<DOC>
	<DOCNO>NCT01421017</DOCNO>
	<brief_summary>This study find optimal dose Imiquimod ( IMQ ) first part ( Phase I ) test effectiveness combination treatment IMQ , cyclophosphamide ( CTX ) , radiotherapy ( RT ) patient skin metastasis breast cancer second part ( Phase II ) . Currently trial Phase II part .</brief_summary>
	<brief_title>Toll-like Receptor ( TLR ) 7 Agonist , Cyclophosphamide , Radiotherapy Breast Cancer With Skin Metastases</brief_title>
	<detailed_description>By harness cytocidal immunostimulatory property two local treatment modality , RT IMQ , effective , adaptive immune response generate , result systemic control metastatic breast cancer local treatment cutaneous metastasis . Additionally , base investigator ' recent preclinical data , investigator intend estimate patient metastatic breast cancer , addition immunomodulatory cyclophosphamide increase anti-tumor response . This trial originally one treatment arm IMQ/RT ( patient treat IMQ RT ) . Recent evidence emerge addition immunomodulatory cyclophosphamide ( CTX ) increase anti-tumor response , therefore IMQ/RT arm close trial continue two additional cohort ( CTX/IMQ/RT CTX/RT ) include cyclophosphamide .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>1 . Patients biopsyconfirmed breast cancer . 2 . Patients least measurable skin metastasis distant , measurable metastasis ( outside skin ) Response Evaluation Criteria Solid Tumors ( RECIST ) . For patient without distant measurable metastasis , area skin metastasis designate receive local therapy substitute . Patients multiple ( &gt; = 2 ) metastatic site ( skin involvement require ) , least one site measurable RECIST , eligible CTX/RT cohort . 3 . Age &gt; = 18 year . 4 . Eastern Cooperative Oncology Group performance status 02 . 5 . Patients must agree tumor fineneedle aspiration require protocol . 6 . Concurrent systemic cancer therapy ( hormone , biologics chemotherapy ) continue distant metastasis nonresponsive ( i.e . complete response partial response ) regimen &gt; = 8 week assess investigator . 7 . Patients must adequate organ bone marrow function define : absolute neutrophil count &gt; = 1,300/microliter hemoglobin &gt; = 9.0 grams/deciliter platelet &gt; = 75,000/microliter total bilirubin = &lt; 1.5 X institutional upper limit normal AST ( aspartate aminotransferase ) = &lt; 2.5 X institutional upper limit normal ALT ( alanine aminotransferase ) = &lt; 2.5 X institutional upper limit normal creatinine = &lt; 2 X institutional upper limit normal patient chronic renal insufficiency creatinine stable &gt; 4 month ) 8 . Informed consent . 1 . Brain metastasis unless resect irradiated stable &gt; = 4 week . 2 . Concurrent treatment investigational agent . 3 . Patients receive local therapy ( radiotherapy , highpotency corticosteroid , intralesional therapy , laser therapy surgery ) biopsy target area within 4 week prior first dose study agent . 4 . Patients receive hyperthermia target area within 10 week prior first dose study agent . 5 . Patients uncontrolled bleed disorder . 6 . Patients ( skin metastasis ) therapeutically anticoagulated heparin coumadin time biopsy ( eligible anticoagulation hold prior biopsy per investigator ) . Patients aspirin platelet agent eligible . 7 . Patients known immunodeficiency receive immunosuppressive therapy . 8 . History allergic reaction imiquimod excipients . 9 . Uncontrolled intercurrent medical illness psychiatric illness/social situation would limit compliance study requirement . 10 . Pregnancy lactation . 11 . Women childbearing potential use medically acceptable mean contraception .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>radiation therapy</keyword>
	<keyword>combination therapy</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>immune response modifier</keyword>
	<keyword>immunostimulatory</keyword>
	<keyword>immunomodulator</keyword>
</DOC>